Clinical Study of Xuebijing Combined with Ulinastatin on Pulmonary Vascular Permeability of Sepsis ARDS

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047452

Enrollment

Unknown

Registered

2021-06-18

Start date

2019-02-28

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis ARDS

Interventions

experimental group:Xuebijing Injection combined with Ulinastatin

control group:Ulinastatin

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Comply with the severe sepsis criteria specified in the 2012 severe sepsis and septic shock treatment guidelines and the 2010 Berlin ARDS definition. 2. The period from the establishment of sepsis ARDS to the inclusion of the trial does not exceed 12 hours, aged 18-80 years. 3. Invasive ventilator treatment is required. 4. Sign informed consent and approved by the hospital ethics committee.

Exclusion criteria

Exclusion criteria: 1. Acute myocardial infarction, acute renal failure, pregnant women, AECOPD, pulmonary interstitial fibrosis, definite valvular heart disease and heart failure. 2. Mental illness and poor control of the condition. 3. Drug users who have not given up drugs. 4. Those who are allergic to related drugs in this treatment.

Design outcomes

Primary

Measure	Time frame
ET-1;thrombomodulin, TM;von Willebrand Factor, vWF;interleukin-6;BALF protein content;Extravascular Lung Water, EVLW;Oxygenation index,OI;	—

Secondary

Measure	Time frame
APACHE II;Sequential Organ Failure Assessment, SOFA;Mechanical ventilation time;Hospital stay;28-day survival rate;	—

Countries

China

Contacts

Public ContactLIU Yuan

liuyuan077@sina.com+86 17734561717

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026